These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 6542375)
1. Hemodynamic profile of the antihypertensive vasodilator cadralazine in conscious dogs. Dorigotti L; Ferni G; Lombroso M; Semeraro C Arzneimittelforschung; 1984; 34(9):984-7. PubMed ID: 6542375 [TBL] [Abstract][Full Text] [Related]
2. Hemodynamic effects of cadralazine in hexamethonium treated and non-treated anesthetized dogs. Higashio T; Tsuji Y; Nakao K; Sakaguchi S; Tanaka M Arzneimittelforschung; 1988 Mar; 38(3):350-8. PubMed ID: 3382459 [TBL] [Abstract][Full Text] [Related]
3. Pharmacological studies of N-(2,5-dimethyl-1H-pyrrol-1-yl)-6-(4-morpholinyl)-3-pyridazinamine hydrochloride (MDL-899), a new long-acting antihypertensive vasodilator. Baldoli E; Bianchi G; Corsico N; Di Francesco GF Arzneimittelforschung; 1985; 35(5):818-26. PubMed ID: 2862874 [TBL] [Abstract][Full Text] [Related]
4. Hemodynamic profile of N-(2,5-dimethyl-1H-pyrrol-1-yl)6-(4-morpholinyl)-3-pyridazinamine hydrochloride in conscious dogs. Di Francesco GF; Baldoli E; Marchetti G; Glässer A Arzneimittelforschung; 1986; 36(1):84-8. PubMed ID: 3954821 [TBL] [Abstract][Full Text] [Related]
5. Systemic, pulmonary and coronary haemodynamic actions of the novel dopamine receptor agonist in awake pigs at rest and during treadmill exercise Z1046. Duncker DJ; Haitsma DB; van der Geest IE; Stubenitsky R; van Meegen JR; Man in't Veld AJ; Verdouw PD Br J Pharmacol; 1997 Mar; 120(6):1101-13. PubMed ID: 9134223 [TBL] [Abstract][Full Text] [Related]
6. Effects of cadralazine on systemic blood pressure, renal function and plasma renin activity in anesthetized dogs. Yukimura T; Miura K; Tanaka M; Higashio T; Sakaguchi S; Kuroda K; Yamamoto K Arzneimittelforschung; 1988 Jan; 38(1):25-8. PubMed ID: 3284531 [TBL] [Abstract][Full Text] [Related]
7. Effects of papaveroline-monosulphate on the systemic and regional circulation in the dog. Data PG; Rolfo A; Cacchio M; Di Tano G Farmaco Sci; 1981 Apr; 36(4):302-14. PubMed ID: 7250364 [TBL] [Abstract][Full Text] [Related]
8. Cardiovascular effects of a novel vasoactive antihypertensive agent, Ro 12-4713. Gerold M; Eigenmann R; Hefti F; Daum A; Haeusler G J Pharmacol Exp Ther; 1981 Mar; 216(3):624-33. PubMed ID: 7009831 [TBL] [Abstract][Full Text] [Related]
9. Systemic and coronary hemodynamic effects of pinacidil, a new antihypertensive agent, in awake dogs: comparison with hydralazine. Kawashima S; Liang CS J Pharmacol Exp Ther; 1985 Feb; 232(2):369-75. PubMed ID: 3968638 [TBL] [Abstract][Full Text] [Related]
10. Generalized cardiovascular and regional hemodynamic effects of meperidine in conscious dogs. Priano LL; Vatner SF Anesth Analg; 1981 Sep; 60(9):649-54. PubMed ID: 7196709 [TBL] [Abstract][Full Text] [Related]
11. Cardiovascular profile of RWJ 29009, a new potassium channel activator, in anesthetized and conscious dogs. Damiano BP; Giardino EC; Haertlein BJ; Stump GL; Mitchell JA; Falotico R J Cardiovasc Pharmacol; 1994 Feb; 23(2):300-10. PubMed ID: 7511761 [TBL] [Abstract][Full Text] [Related]
12. Hemodynamic effects of cadralazine or chlorthalidone in verapamil-treated elderly hypertensives. Antonicelli R; Savonitto S; Tomassini PF; Gambini C; Sardina M; Paciaroni E Int J Clin Pharmacol Ther; 1994 Apr; 32(4):198-203. PubMed ID: 8032580 [TBL] [Abstract][Full Text] [Related]
13. Intravenous infusion of phentolamine: effects on cardiovascular dynamics and regional blood flow distribution in conscious dogs. Dumont L; Lamoureux C; Lelorier J; Stanley P; Chartrand C J Cardiovasc Pharmacol; 1982; 4(6):1055-61. PubMed ID: 6185772 [TBL] [Abstract][Full Text] [Related]
14. Functional role of alpha-calcitonin gene-related peptide in the regulation of the cardiovascular system. Shen YT; Pittman TJ; Buie PS; Bolduc DL; Kane SA; Koblan KS; Gould RJ; Lynch JJ J Pharmacol Exp Ther; 2001 Aug; 298(2):551-8. PubMed ID: 11454916 [TBL] [Abstract][Full Text] [Related]
15. Pharmacological studies on cadralazine: a new antihypertensive vasodilator drug. Semeraro C; Dorigotti L; Banfi S; Carpi C J Cardiovasc Pharmacol; 1981; 3(3):455-67. PubMed ID: 6168827 [TBL] [Abstract][Full Text] [Related]
16. [Influence of acetylation phenotype on the pharmacokinetics and pharmacodynamics data of cadralazine in normotensive subjects]. Brunel P; Lecaillon JB; Imhof P; Menard J Arch Mal Coeur Vaiss; 1989 Jul; 82(7):1257-60. PubMed ID: 2510657 [TBL] [Abstract][Full Text] [Related]
17. Effect of mefenidil on cerebral and peripheral hemodynamics in dogs. Koehler RC; Wilson DA; Rogers MC; Traystman RJ J Pharmacol Exp Ther; 1985 May; 233(2):327-32. PubMed ID: 3999024 [TBL] [Abstract][Full Text] [Related]
18. Cardiovascular effects of three calcium entry blockers in conscious dogs. Eigenmann R; Gerold M Arzneimittelforschung; 1987 Sep; 37(9):1020-5. PubMed ID: 3435596 [TBL] [Abstract][Full Text] [Related]
19. Cardiovascular pharmacology of 6-[4-(4'-pyridyl)aminophenyl]-4,5-dihydro-3(2H)-pyridazinone hydrochloride, a novel and potent cardiotonic agent with vasodilator properties. Narimatsu A; Kitada Y; Satoh N; Suzuki R; Okushima H Arzneimittelforschung; 1987 Apr; 37(4):398-406. PubMed ID: 3606694 [TBL] [Abstract][Full Text] [Related]
20. Acute systemic and renal haemodynamic effects and long-term antihypertensive action of cadralazine in patients pretreated with beta-blockers and diuretics. Persson B; Granerus G; Wysocki M; Hedner T; Andersson OK Eur J Clin Pharmacol; 1987; 31(5):513-8. PubMed ID: 2881788 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]